GlassScriptPhysician profile
Harold M Brown
NPI 1760486294
$14,959.94
in general payments reported to CMS, 2019-2025
48 companies · $3,494 in 2025
The $3,494 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,379 · 2020: $1,652 · 2021: $1,003 · 2022: $933 · 2023: $2,053 · 2024: $3,447 · 2025: $3,494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,938 · Education: $55.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,937.86 |
| Education | $55.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,450.18 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $1,407.36 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Pfizer INC. | $1,349.64 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,171.72 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,143.62 | 2019-2025 | |
| Amgen INC. | $813.28 | 2019-2025 | Repatha, Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $745.53 | 2019-2025 | Spravato, Xarelto |
| Lilly USA, LLC | $670.38 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $658.43 | 2019-2024 | Xifaxan, Trulance |
| Corcept Therapeutics | $634.38 | 2023-2025 | Korlym |
| Novo Nordisk INC | $545.87 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $405.17 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Esperion Therapeutics, INC. | $398.41 | 2020-2025 | Nexletol |
| Phathom Pharmaceuticals, INC. | $356.45 | 2024-2025 | Voquezna |
| Allergan, INC. | $319.66 | 2019-2020 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harold Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.